サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1378873

神経変性疾患治療市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測

Neurodegenerative Disease Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 143 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
神経変性疾患治療市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測
出版日: 2023年11月02日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

世界の神経変性疾患治療市場規模は2022年に709億米ドルに達しました。今後、IMARC Groupは、2022年から2028年にかけて5.4%の成長率（CAGR）を示し、2028年までに972億米ドルに達すると予測しています。

神経変性疾患とは、中枢神経系（CNS）または末梢神経系（PNS）のニューロンの構造と機能が進行性に変性する脳疾患群を指します。現在、身体的あるいは精神的症状を軽減し、患者の生活の質を改善するために、いくつかの薬剤が利用可能です。さらに研究者は、神経変性疾患を早期に発見・診断し、その進行を予防するための分子診断法、特にバイオマーカーや画像分光法の開発に注力しています。

過度のアルコール摂取に起因する腫瘍や脳卒中の有病率の増加は、高齢者人口の増加と相まって、神経変性疾患の発症リスクを高める主要な要因の一つとなっています。このことは、アルツハイマー病、パーキンソン病、ハンチントン病、筋萎縮性側索硬化症などの神経変性疾患の早期診断のための分子診断技術の必要性をさらに高めています。これとは別に、研究者たちはこれらの疾患の分類を効果的に理解するために、神経病理学的手法と分子生物学的手法を組み合わせています。また、さまざまなタイプの神経変性疾患に対する低侵襲（MI）スクリーニング検査の開発も進められています。さらに，神経変性疾患の危険因子についての認識を高めるために，非政府組織（NGO）とともに，多くの国の行政機関がさまざまな健康教育キャンペーンを支援しています。インフラの改善によるヘルスケア施設へのアクセスの増加や可処分所得の増加といったその他の要因も、今後数年間の市場の成長を促進すると予想されます。

本レポートで扱う主な質問

  • 神経変性疾患治療の世界市場はこれまでどのように推移し、今後どのように推移していくのか？
  • COVID-19が世界の神経変性疾患治療薬市場に与えた影響は？
  • 主要な地域市場は？
  • 適応症別の市場内訳は？
  • 薬剤タイプ別の市場内訳は？
  • 投与経路に基づく市場内訳は？
  • 販売チャネル別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主な促進要因と課題は何か？
  • 世界の神経変性疾患治療薬市場の構造と主要プレイヤーは？
  • 業界における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 神経変性疾患治療の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：適応症別

  • 多発性硬化症
    • 市場動向
    • 市場予測
  • パーキンソン病
    • 市場動向
    • 市場予測
  • アルツハイマー病
    • 市場動向
    • 市場予測
  • 脊髄性筋萎縮症（SMA）
    • 市場動向
    • 市場予測
  • ハンチントン病
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：薬剤タイプ別

  • N-メチル-D-アスパラギン酸受容体拮抗薬
    • 市場動向
    • 市場予測
  • 選択的セロトニン再取り込み阻害薬
    • 市場動向
    • 市場予測
  • ドーパミン阻害薬
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：投与経路別

  • 経口
    • 市場動向
    • 市場予測
  • 注射
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • 小売薬局
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第10章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Biogen
    • Boehringer Ingelheim International GmbH
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline Plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A
    • Teva Pharmaceutical Industries Ltd.
    • UCB S.A
図表

List of Figures

  • Figure 1: Global: Neurodegenerative Disease Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Neurodegenerative Disease Treatment Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Neurodegenerative Disease Treatment Market: Breakup by Indication (in %), 2022
  • Figure 5: Global: Neurodegenerative Disease Treatment Market: Breakup by Drug Type (in %), 2022
  • Figure 6: Global: Neurodegenerative Disease Treatment Market: Breakup by Route of Administration (in %), 2022
  • Figure 7: Global: Neurodegenerative Disease Treatment Market: Breakup by Distribution Channel (in %), 2022
  • Figure 8: Global: Neurodegenerative Disease Treatment Market: Breakup by Region (in %), 2022
  • Figure 9: Global: Neurodegenerative Disease Treatment (Multiple Sclerosis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Neurodegenerative Disease Treatment (Multiple Sclerosis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Neurodegenerative Disease Treatment (Parkinson's Disease) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Neurodegenerative Disease Treatment (Parkinson's Disease) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Neurodegenerative Disease Treatment (Alzheimer's Disease) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Neurodegenerative Disease Treatment (Alzheimer's Disease) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Neurodegenerative Disease Treatment (Spinal Muscular Atrophy- SMA) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Neurodegenerative Disease Treatment (Spinal Muscular Atrophy- SMA) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Neurodegenerative Disease Treatment (Huntington's Disease) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Neurodegenerative Disease Treatment (Huntington's Disease) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Neurodegenerative Disease Treatment (Others) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Neurodegenerative Disease Treatment (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Neurodegenerative Disease Treatment (N-methyl-D-aspartate Receptor Antagonists) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Neurodegenerative Disease Treatment (N-methyl-D-aspartate Receptor Antagonists) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Neurodegenerative Disease Treatment (Selective Serotonin Reuptake Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Neurodegenerative Disease Treatment (Selective Serotonin Reuptake Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: Global: Neurodegenerative Disease Treatment (Dopamine Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: Global: Neurodegenerative Disease Treatment (Dopamine Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: Global: Neurodegenerative Disease Treatment (Others) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: Global: Neurodegenerative Disease Treatment (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Global: Neurodegenerative Disease Treatment (Oral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Global: Neurodegenerative Disease Treatment (Oral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: Global: Neurodegenerative Disease Treatment (Injectable) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: Global: Neurodegenerative Disease Treatment (Injectable) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: Global: Neurodegenerative Disease Treatment (Others) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: Global: Neurodegenerative Disease Treatment (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: Global: Neurodegenerative Disease Treatment (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: Global: Neurodegenerative Disease Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: Global: Neurodegenerative Disease Treatment (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: Global: Neurodegenerative Disease Treatment (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: Global: Neurodegenerative Disease Treatment (Others) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: Global: Neurodegenerative Disease Treatment (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: North America: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: North America: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: United States: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: United States: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: Canada: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: Canada: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: Asia-Pacific: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: Asia-Pacific: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: China: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: China: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: Japan: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: Japan: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: India: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: India: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: South Korea: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: South Korea: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: Australia: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: Australia: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Indonesia: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Indonesia: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: Others: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: Others: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Europe: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Europe: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: Germany: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: Germany: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: France: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: France: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: United Kingdom: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: United Kingdom: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Italy: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: Italy: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Spain: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 74: Spain: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Russia: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 76: Russia: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Others: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 78: Others: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 79: Latin America: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 80: Latin America: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 81: Brazil: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 82: Brazil: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 83: Mexico: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 84: Mexico: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 85: Others: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 86: Others: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 87: Middle East and Africa: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 88: Middle East and Africa: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 89: Middle East and Africa: Neurodegenerative Disease Treatment Market: Breakup by Country (in %), 2022
  • Figure 90: Global: Neurodegenerative Disease Treatment Industry: SWOT Analysis
  • Figure 91: Global: Neurodegenerative Disease Treatment Industry: Value Chain Analysis
  • Figure 92: Global: Neurodegenerative Disease Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Neurodegenerative Disease Treatment Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Neurodegenerative Disease Treatment Market Forecast: Breakup by Indication (in Million US$), 2023-2028
  • Table 3: Global: Neurodegenerative Disease Treatment Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
  • Table 4: Global: Neurodegenerative Disease Treatment Market Forecast: Breakup by Route of Administration (in Million US$), 2023-2028
  • Table 5: Global: Neurodegenerative Disease Treatment Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 6: Global: Neurodegenerative Disease Treatment Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 7: Global: Neurodegenerative Disease Treatment Market: Competitive Structure
  • Table 8: Global: Neurodegenerative Disease Treatment Market: Key Players
目次
Product Code: SR112023A3102

Abstract

The global neurodegenerative disease treatment market size reached US$ 70.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 97.2 Billion by 2028, exhibiting a growth rate (CAGR) of 5.4% during 2022-2028.

Neurodegenerative diseases refer to a group of brain disorders that lead to progressive degeneration of the structure and function of neurons in the central nervous system (CNS) or peripheral nervous system (PNS). Presently, several medications are available to reduce physical or mental symptoms and improve the quality of patients' life. Moreover, researchers are focusing on developing molecular diagnostics, especially biomarkers and imaging spectroscopy, to detect and diagnose neurodegenerative diseases at an early stage and prevent their progression.

The growing prevalence of tumors and stroke on account of excessive alcohol consumption, in confluence with the rising geriatric population, represents one of the major factors increasing the risk of developing neurodegenerative diseases. This is further escalating the need for molecular diagnostic techniques for early diagnosis of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Apart from this, researchers are combining neuropathological methods with molecular biology techniques to understand the classification of these diseases effectively. They are also developing minimally invasive (MI) screening tests for different types of neurodegenerative diseases. Furthermore, governing agencies of numerous countries, along with non-governmental organizations (NGOs), are supporting various health education campaigns to generate awareness about the risk factors of neurodegenerative diseases. Other factors, such as increasing access to healthcare facilities on account of improving infrastructure and inflating disposable incomes, are anticipated to drive the growth of the market in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global neurodegenerative disease treatment market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on indication, drug type, route of administration and distribution channel.

Breakup by Indication:

Multiple Sclerosis

Parkinson's Disease

Alzheimer's Disease

Spinal Muscular Atrophy (SMA)

Huntington's Disease

Others

Breakup by Drug Type:

N-methyl-D-aspartate Receptor Antagonists

Selective Serotonin Reuptake Inhibitors

Dopamine Inhibitors

Others

Breakup by Route of Administration:

Oral

Injectable

Others

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Biogen, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. and UCB S.A.

Key Questions Answered in This Report:

  • How has the global neurodegenerative disease treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global neurodegenerative disease treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global neurodegenerative disease treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Neurodegenerative Disease Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Indication

  • 6.1 Multiple Sclerosis
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Parkinson's Disease
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alzheimer's Disease
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Spinal Muscular Atrophy (SMA)
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Huntington's Disease
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 N-methyl-D-aspartate Receptor Antagonists
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Selective Serotonin Reuptake Inhibitors
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Dopamine Inhibitors
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Biogen
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Boehringer Ingelheim International GmbH
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 F. Hoffmann-La Roche AG
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
    • 15.3.4 GlaxoSmithKline Plc
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 SWOT Analysis
    • 15.3.5 Merck & Co. Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Novartis AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Pfizer Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Sanofi S.A
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Teva Pharmaceutical Industries Ltd.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 UCB S.A
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis